⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
GLP-1 Receptor Agonist Market Report 2026
globenewswire.com
NVO
SNY
LLY
Wellness Clinic Prana IV Therapy Discusses Nutritional Gaps Linked to GLP-1 Weight Loss Drugs
prnewswire.com
NVO
LLY
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
globenewswire.com
MMA
NVO
HIMS
LLY
Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight
prnewswire.com
NVO
BMY
JNJ
AMGN
REGN
SNY
PFE
AZN
LLY
NVS
ForePass Replicates Effects of the Most Powerful and Invasive Bariatric Surgery While Dramatically Outperforming Leading GLP-1
businesswire.com
NVO
Pharmaceutical Companies Face Growing Pressure to Govern AI in Regulated Environments
globenewswire.com
JNJ
MRK
NVO
SNY
GSK
Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic
prnewswire.com
ABBV
AZN
BMY
LLY
NVO
Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion
globenewswire.com
GILD
NVS
BMY
NVO
Etavopivat Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
globenewswire.com
NVO
Journées ESGE 2026 : Une étude révèle que la procédure endoscopique est associée à une perte de poids à court terme plus importante que le semaglutide oral USA - Français USA - English USA - Deutsch USA - español
prnewswire.com
NVO